MedTrace Logo

Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)

NCT00822094 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2017-11-24

Study results available
· View outcomes & findings →

Summary

The study investigates if CPX-351 will be a) more effective than the standard intensive salvage AML treatment and b) more tolerable than the standard intensive salvage treatment regimens.

The study compares the investigational product CPX-351 vs the standard intensive salvage treatment for first relapse AML patients.

Conditions

Interventions

DRUG

CPX-351

DRUG

Intensive Salvage Therapy

Sponsors & Collaborators

Principal Investigators

  • Jonathan Kolitz, MD · North Shore University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-12-31
Completion
2012-01-31

Countries

  • United States
  • Canada
  • France
  • Poland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822094 on ClinicalTrials.gov